Mexico cuts drug trial approvals to 30 days, draws $643 million in pharma investment
COFEPRIS reduced clinical trial authorization from 120 to 30 days as of the Scientific Conference 2026. Boehringer Ingelheim, Bayer, AstraZeneca, and Camber-Amarox committed more than US$643 million to manufacturing and research over the past 14 months, citing regulatory speed.
Our reading
Faster regulatory approval has directly enabled capital commitments to Mexican pharmaceutical infrastructure. Executives have named permitting speed as a factor in expansion decisions, translating procedural reform into measured facility investment.
Mexico's Ministry of Health established a Permanent Interinstitutional Board for Clinical Protocols in January 2026, coordinating ethics and regulatory review among COFEPRIS, the National Center for Research and Health Evaluation, and the National Commission of Bioethics. The board operates within Plan Mexico, the government's nearshoring framework.
Next
Watch for production start-dates and capacity installations at the committed facilities. A meaningful shift would be sustained trial volume in Mexico exceeding prior-year levels, demonstrable through COFEPRIS public registries if available.